Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs JD.Com Inc (JD) Price & Performance

Boston Scientific CorporationTrade
JD.Com IncTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs JD.Com Inc — how do they compare? Boston Scientific Corporation trades at $42.51 (market cap $66.37B), while JD.Com Inc trades at $29.39 (market cap $39.64B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and JD.Com Inc pays a 3.47% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

BSXJD
Market Cap
$66.37B$39.64B
Sector
HealthConsumer Cyclical
52-Week High
$108.14$36.17
52-Week Low
$42.63$25.19
Enterprise Value
$75.94B$25.80B
Dividend Yield
3.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.

BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.

JD.Com Inc

JD.com trades at $28.88, up 2.41% today, with strong technical momentum and bullish analyst sentiment. Recent earnings beats and a consensus price target of $40 suggest significant upside potential. The company maintains robust revenue growth, reaching $1.31 trillion in 2025, though net margins compressed to 1.05%. Positive news highlights retail margin expansion and AI-driven investments.

Outlook remains favorable with Wall Street's 70% buy rating, but risks include Chinese regulatory scrutiny and ongoing margin pressures. The stock's current valuation at P/E 21.2 appears reasonable given growth prospects, though investors should monitor earnings sustainability and geopolitical factors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About JD.Com Inc

JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.

Read more on JD